A 52-year-old woman, without a history of psoriasis, developed a widespread, sterile pustular eruption on the trunk and extremities 2 days after subcutaneous injection of dexamethasone solution. Skin biopsy revealed subcorneal pustules filled with neutrophils and moderate lymphohistiocytic infiltrate with a few eosinophils in the dermis. There was no evidence of vasculitis. Patch testing showed positive pustular reactions to dexamethasone solution. Histology of this pustule also resembled that of the original eruption. To our knowledge, acute generalized exanthematous pustulosis due to corticosteroid has not been previously reported.

Owing to human labor shortages, the automation of labor-intensive manual waste-sorting is needed. The goal of automating waste-sorting is to replace the human role of robust detection and agile manipulation of waste items with robots. To achieve this, we propose three methods. First, we provide a combined manipulation method using graspless push-and-drop and pick-and-release manipulation. Second, we provide a robotic system that can automatically collect object images to quickly train a deep neuralnetwork model. Third, we provide a method to mitigate the differences in the appearance of target objects from two scenes: one for dataset collection and the other for waste sorting in a recycling factory. If differences exist, the performance of a trained waste detector may decrease. We address differences in illumination and background by applying object scaling, histogram matching with histogram equalization, and background synthesis to the source target-object images. Via experiments in an indoor experimental workplace for waste-sorting, we confirm that the proposed methods enable quick collection of the training image sets for three classes of waste items (i.e., aluminum can, glass bottle, and plastic bottle) and detection with higher performance than the methods that do not consider the differences. We also confirm that the proposed method enables the robot quickly manipulate the objects.

No abstract

Apalutamide, an oral androgen receptor signaling inhibitor, is approved for the treatment of nonmetastatic castration-resistant prostate cancer and metastatic prostate cancer. In the international randomized placebo-controlled clinical trials, apalutamide was associated with a higher rate of rash than placebo. However, given that reports from a dermatological perspective are limited, the skin manifestations and histopathology of the skin lesions caused by apalutamide are largely unknown. Here, we report a case of apalutamide-induced drug eruption. A 66-year-old man developed itchy maculopapular erythema on the trunk and extremities 10 weeks after starting apalutamide for progressive prostate cancer. A biopsy specimen showed interface dermatitis with perivascular lymphocytic infiltration in the upper dermis. The lymphocyte transformation test was positive for apalutamide. The skin manifestations improved after discontinuation of apalutamide and treatment with topical corticosteroids and systemic prednisolone. A review of the dermatology literature on apalutamide-induced drug eruption yielded only six cases, including our case. Dermatologically, there were four cases of maculopapular rash and two of toxic epidermal necrolysis and histopathologically, there were three cases of interface dermatitis, two of epidermal necrosis, and one of spongiotic dermatitis. Four patients had peripheral eosinophilia.A lymphocyte transformation test was performed in three cases and was positive for apalutamide in all cases. Except for the two cases of toxic epidermal necrolysis, which were fatal, the skin eruptions appeared 10 weeks after starting apalutamide. Considering the increasing number of patients with prostate cancer being treated with apalutamide, cases of apalutamide-induced drug eruption need to be accumulated and analyzed.

No abstract